Neurocrine Biosciences (NBIX) Cash from Financing Activities (2010 - 2026)

Neurocrine Biosciences' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$86.1 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 26.97% year-over-year to -$86.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.5 million (up 99.04% YoY) and the FY2025 annual result came in at -$38.3 million, up 92.13% from the prior year.
• Cash from Financing Activities was -$86.1 million for Q1 2026 at Neurocrine Biosciences, down from $37.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $69.9 million in Q1 2024 and bottomed at -$293.0 million in Q2 2024.
• A 5-year average of -$45.9 million and a median of $8.2 million in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 1266.67% — and 2024, when it plunged 10203.45%.
• Neurocrine Biosciences' Cash from Financing Activities stood at $24.6 million in 2022, then surged by 43.9% to $35.4 million in 2023, then slumped by 919.21% to -$290.0 million in 2024, then jumped by 112.86% to $37.3 million in 2025, then sank by 330.83% to -$86.1 million in 2026.
• Business Quant data shows NBIX's Cash from Financing Activities at -$86.1 million in Q1 2026, $37.3 million in Q4 2025, and $45.6 million in Q3 2025.